{
    "Trade/Device Name(s)": [
        "cobas SARS-CoV-2 Qualitative for use on the cobas 5800/6800/8800 Systems"
    ],
    "Submitter Information": "Roche Molecular Systems, Inc.",
    "510(k) Number": "K240867",
    "Predicate Device Reference 510(k) Number(s)": [
        "K231306"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QQX"
    ],
    "Summary Letter Date": "February 11, 2025",
    "Summary Letter Received Date": "February 11, 2025",
    "Submission Date": "February 11, 2025",
    "Regulation Number(s)": [
        "21 CFR 866.3981"
    ],
    "Regulation Name(s)": [
        "Device To Detect And Identify Nucleic Acid Targets In Respiratory Specimens From Microbial Agents That Cause The SARS-Cov-2 Respiratory Infection And Other Microbial Agents When In A Multi-Target Test"
    ],
    "Analyte Class(es)": [
        "virology",
        "genetic molecular"
    ],
    "Analyte(s)": [
        "SARS-CoV-2 RNA"
    ],
    "Specimen Type(s)": [
        "Nasopharyngeal swab",
        "Anterior nasal swab"
    ],
    "Specimen Container(s)": [
        "Copan Universal Transport Medium System (UTM-RT)",
        "BD Universal Viral Transport System (UVT)",
        "cobas PCR Media",
        "0.9% physiological saline"
    ],
    "Instrument(s)/Platform(s)": [
        "cobas 5800 System",
        "cobas 6800 System",
        "cobas 8800 System"
    ],
    "Method(s)/Technology(ies)": [
        "Real-time RT-PCR",
        "Nucleic acid extraction and purification",
        "TaqMan probe-based fluorescence detection"
    ],
    "Methodologies": [
        "RT-PCR",
        "Real-time PCR",
        "Molecular detection"
    ],
    "Submission Type(s)": [
        "Test",
        "Assay",
        "Reagent",
        "System"
    ],
    "Document Summary": "FDA 510(k) summary for cobas SARS-CoV-2 Qualitative real-time RT-PCR assay for detection of SARS-CoV-2 RNA on cobas 5800/6800/8800 platforms",
    "Indications for Use Summary": "Intended for qualitative detection of nucleic acids from SARS-CoV-2 in nasopharyngeal swabs from symptomatic individuals and anterior nasal swabs from any individuals, used in conjunction with clinical assessment.",
    "fda_folder": "Microbiology"
}